Teva's Biosimilar Push Tests Biologics Scale-Up Capacity

Teva Pharmaceutical is accelerating its biosimilar portfolio at a pace that will stress-test its biologics manufacturing infrastructure. With FDA approval of PONLIMSI (denosumab) across all indications of reference product Prolia, and an FDA and EMA-accepted filing for its omalizumab biosimilar candidate, Teva is compressing the timeline toward its stated target of $800 million in biosimilar revenues by 2027 -- a goal that carries significant implications for batch release capacity, comparability protocols, and supply chain qualification across its biologics network.

Q1 2026 revenues reached approximately $4.0 billion, a 2% increase year-over-year in U.S. dollars, though a 3% decline in local currency terms. The headline growth was driven by the innovative portfolio: AUSTEDO posted global revenues of $578 million, up 41% year-over-year in local currency; AJOVY reached $196 million, up 35%; and UZEDY recorded $63 million, up 62%. Collectively, these three brands grew 41% year-over-year in local currency. Offsetting gains, global generics revenues fell 16% year-over-year in local currency, driven primarily by increased competition on lenalidomide capsules and the divestment of the Japan business venture in Q1 2025.

The late-stage pipeline adds further regulatory and manufacturing complexity. The FDA accepted Teva's NDA for an olanzapine long-acting injectable in February 2026, with a targeted Q4 2026 launch subject to approval, and EU MAA acceptance expected in Q2 2026. Phase 3 enrollment for duvakitug, an anti-TL1A candidate, is on target following Phase 2b maintenance data showing durable efficacy in ulcerative colitis and Crohn's disease. Teva also announced plans to acquire Emalex Biosciences, adding an NDA-ready neuroscience asset, with the transaction anticipated to close by Q3 2026 pending regulatory approvals.

For QA directors and plant heads, the convergence of biosimilar approvals, a long-acting injectable launch, and an acquisition-driven pipeline addition within a compressed window raises practical questions about validated manufacturing capacity, technology transfer timelines, and post-approval change management under 21 CFR Part 211 and ICH Q10 frameworks. Teva has guided for full-year 2026 revenues of $16.4 to $16.8 billion and a non-GAAP operating income of $3.80 to $4.0 billion, updated to reflect an expected $700 million IPR&D charge related to the Emalex transaction. The company separately targets approximately $700 million in net savings by 2027 and a 30% non-GAAP operating income margin by the same year.